IBDEI0MB ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10186,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10186,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,10186,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,10186,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,10187,0)
 ;;=L50.9^^68^664^286
 ;;^UTILITY(U,$J,358.3,10187,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10187,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,10187,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,10187,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,10188,0)
 ;;=L53.8^^68^664^147
 ;;^UTILITY(U,$J,358.3,10188,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10188,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,10188,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,10188,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,10189,0)
 ;;=L53.9^^68^664^146
 ;;^UTILITY(U,$J,358.3,10189,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10189,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,10189,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,10189,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,10190,0)
 ;;=L54.^^68^664^145
 ;;^UTILITY(U,$J,358.3,10190,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10190,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,10190,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,10190,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,10191,0)
 ;;=L56.0^^68^664^139
 ;;^UTILITY(U,$J,358.3,10191,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10191,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,10191,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,10191,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,10192,0)
 ;;=L56.1^^68^664^138
 ;;^UTILITY(U,$J,358.3,10192,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10192,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,10192,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,10192,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,10193,0)
 ;;=L56.2^^68^664^236
 ;;^UTILITY(U,$J,358.3,10193,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10193,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,10193,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,10193,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,10194,0)
 ;;=L56.3^^68^664^268
 ;;^UTILITY(U,$J,358.3,10194,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10194,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,10194,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,10194,2)
 ;;=^5009217
 ;;^UTILITY(U,$J,358.3,10195,0)
 ;;=L57.0^^68^664^12
 ;;^UTILITY(U,$J,358.3,10195,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10195,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,10195,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,10195,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,10196,0)
 ;;=L60.0^^68^664^161
 ;;^UTILITY(U,$J,358.3,10196,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10196,1,3,0)
 ;;=3^Ingrowing Nail
 ;;^UTILITY(U,$J,358.3,10196,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,10196,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,10197,0)
 ;;=L60.1^^68^664^234
 ;;^UTILITY(U,$J,358.3,10197,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10197,1,3,0)
 ;;=3^Onycholysis
 ;;^UTILITY(U,$J,358.3,10197,1,4,0)
 ;;=4^L60.1
 ;;^UTILITY(U,$J,358.3,10197,2)
 ;;=^186837
 ;;^UTILITY(U,$J,358.3,10198,0)
 ;;=L60.2^^68^664^233
 ;;^UTILITY(U,$J,358.3,10198,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10198,1,3,0)
 ;;=3^Onychogryphosis
 ;;^UTILITY(U,$J,358.3,10198,1,4,0)
 ;;=4^L60.2
 ;;^UTILITY(U,$J,358.3,10198,2)
 ;;=^5009235
 ;;^UTILITY(U,$J,358.3,10199,0)
 ;;=L60.3^^68^664^170
 ;;^UTILITY(U,$J,358.3,10199,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10199,1,3,0)
 ;;=3^Nail Dystrophy
 ;;^UTILITY(U,$J,358.3,10199,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,10199,2)
 ;;=^5009236
